- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05081999
De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease (ABBREVIATE)
De-Adoption βeta-Blockers in Patients With Stable Ischemic Heart Disease Without REduced LV Ejection Fraction, Ongoing Ischemia, or Arrhythmias: a pragmaTic randomizEd Trial With Blinded Endpoints
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Sean van Diepen, MD
- Phone Number: 587-990-5746
- Email: sv9@ualberta.ca
Study Contact Backup
- Name: Karin Kushniruk, RN, PhD
- Phone Number: 780-492-8476
- Email: karin.kushniruk@ualberta.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Recruiting
- University of Alberta Hospital
-
Contact:
- Sean van Diepen, MD
- Phone Number: 587-990-5746
- Email: sv9@ualberta.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >21 years
Documented Coronary Artery Disease (CAD) defined as:
- Myocardial Infarction at least 6 months prior; or
Stable ischemic heart disease (defined using one of the following tests suggestive of significant coronary artery disease):
i. Positive exercise stress test ii. Positive Nuclear perfusion scan iii. Positive exercise or pharmacologic echocardiographic stress test iv. Positive magnetic resonance imaging coronary perfusion scan v. Coronary computed tomographic angiography Angiogram with stenosis ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing by CT (FFRCT); vi. Invasive coronary angiography with ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing (FFR) or instant wave free ratio (IFR),
- Previous Percutaneous Coronary Intervention (PCI, at least 6 months prior if revascularization is performed for an MI); or
- Previous Coronary Artery Bypass Grafting (CABG, at least 6 months prior if revascularization is performed for an MI)
- Able and willing to provide informed consent
Exclusion Criteria:
- Left Ventricular Ejection Fraction < 40% or current hospitalization for heart failure
- Myocardial infarction <6 months prior to randomization
- Indication for β-blocker as determined by the treating physician (such as atrial or ventricular arrhythmias or ongoing angina not controlled by another agent)
- Uncontrolled hypertension or uncontrolled angina symptoms (per the Investigator's discretion)
- Non-compliance with medical therapy
- Life expectancy <1 year
- Participation in another trial related to β-blockers or other anti-anginal drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Continuation of Beta-Blockers
For patients already on β-blocker therapy, the treatment will be continued and titrated at the discretion of the patient's most responsible physician(s).
|
medical hx, events inquiry, adherence to treatment arm periodically over 4 years
online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
|
Other: De-Adoption of Beta-Blockers
For patients on β-blocker therapy, medication will be tapered over 3-7 days to minimize the potential for withdrawal-related symptoms.
A standardized angina treatment algorithm, which is independent of β-blocker use, will minimize any worsening of angina symptoms during drug withdrawal by utilizing other guideline recommended anti-anginal agents, such as calcium-channel blockers, long acting nitrates, or ivabradine.
An anticipated 5% of patients allocated to this arm will not be able to tolerate discontinuation, however, patients will continue participation as per intention-to-treat principle.
Background lifestyle measures and medical therapies will be recommended according to current Canadian guideline recommendations and individual patient profiles.
Structured algorithms to achieve blood pressure goals that exclude the use of a β-blocker based on the Canadian Hypertension Education Program Guidelines will be provided.
|
medical hx, events inquiry, adherence to treatment arm periodically over 4 years
online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of time to first all-cause death, non-fatal MI, or hospitalization for resuscitated cardiac arrest, unstable angina requiring urgent revascularization or heart failure over an estimated four years
Time Frame: 4 years post randomization
|
Composite of time to first all-cause death, non-fatal MI, or hospitalization for resuscitated cardiac arrest, unstable angina requiring urgent revascularization or heart failure over an estimated four years
|
4 years post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
individual components of the primary objective (including all-cause death, non-fatal MI, or hospitalization for resuscitated cardiac arrest, unstable angina requiring urgent revascularization or HF)
Time Frame: 4 years post randomization
|
individual components of the primary objective (including all-cause death, non-fatal MI, or hospitalization for resuscitated cardiac arrest, unstable angina requiring urgent revascularization or HF)
|
4 years post randomization
|
stroke
Time Frame: 4 years post randomization
|
stroke
|
4 years post randomization
|
angina related quality of life
Time Frame: 4 years post randomization
|
angina related quality of life as measured by the Seattle Angina Questionnaire
|
4 years post randomization
|
sexual function
Time Frame: 4 years post randomization
|
sexual function as measured by the IIEF-5 and FSFI
|
4 years post randomization
|
new onset diabetes
Time Frame: 4 years post randomization
|
new onset diabetes
|
4 years post randomization
|
drug withdrawal
Time Frame: 4 years post randomization
|
stop/re-start dates
|
4 years post randomization
|
health care costs in each arm
Time Frame: 4 years post randomization
|
health care costs in each arm
|
4 years post randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sean van Diepen, MD, University of Alberta
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00113192
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Medical Assessment
-
Medical University of ViennaUnknown
-
National Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
Centre Hospitalier Henri Duffaut - AvignonRecruitingChronic Myelogenous Leukemia - Chronic PhaseFrance
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; Tata Memorial Hospital; Udaan TrustNot yet recruitingHIV InfectionUnited States, India
-
Jennifer HrabeRecruiting
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedLymphedemaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedDepression | Pain | Malnutrition | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid Cancer | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Weight ChangesUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Not yet recruitingHIV Infection | Human Papillomavirus Infection | Human Papillomavirus-Related CarcinomaUnited States, India
-
University of Southern CaliforniaNational Cancer Institute (NCI); NovoCure Ltd.WithdrawnOligoastrocytoma | Oligodendroglioma | Anaplastic OligodendrogliomaUnited States
-
Tilak HealthcareCompleted